BiotechTube

Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postoperative Local Analgesia

Conditions

Postoperative Local Analgesia

Trial Timeline

Jun 9, 2025 → Jul 21, 2025

NCT ID
NCT07279155

About Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation

Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Postoperative Local Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT07279155. Target conditions include Postoperative Local Analgesia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07279155Phase 1Completed

Competing Products

20 competing products in Postoperative Local Analgesia

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 2
52
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
85
Lemborexant 5 mg + Control (placebo) groupEisaiPhase 2
52
Ondansetron + PalonosetronEisaiPhase 2
52
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
52
ONO-1101Ono PharmaceuticalPhase 2
52
ONO-1101Ono PharmaceuticalPhase 2/3
65
Levofloxacin Ophthalmic + CefuroximeSanten PharmaceuticalPhase 1/2
41
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic SolutionSanten PharmaceuticalPhase 1/2
41
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
77
SHR8554 InjectionJiangsu Hengrui MedicinePhase 1
33
EsomeprazoleAstraZenecaApproved
85
deep neuromuscular blockMerckPre-clinical
23
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
52
MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
85
MK0719MerckPhase 2
52
Sugammadex + NeostigmineMerckApproved
85
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
77
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85